{"groups":[{"description":"Participants with relapsed/refractory mantle cell lymphoma (MCL) received conditioning chemotherapy (CTE) consisting of fludarabine 30 mg/m\\^2/day and cyclophosphamide 500 mg/m\\^2/day intravenous (IV) infusion for 3 days followed by a single infusion of axicabtagene ciloleucel at a targeted dose of 2 x 10\\^6 anti-CD19 chimeric antigen receptor (CAR) T cells/kg on Day 0.","id":"FG000","title":"2 x 10^6 Axicabtagene Ciloleucel"},{"description":"Participants with relapsed/refractory MCL received CTE consisting of fludarabine 30 mg/m\\^2/day and cyclophosphamide 500 mg/m\\^2/day IV infusion for 3 days followed by a single infusion of brexucabtagene autoleucel at a targeted dose of 2 x 10\\^6 anti-CD19 CAR T cells/kg, with a maximum dose of 2 x 10\\^8 anti-CD19 CAR T cells for participants ≥ 100 kg on Day 0.","id":"FG001","title":"Cohort 1: 2 x 10^6 Brexucabtagene Autoleucel"},{"description":"Participants with relapsed/refractory MCL received conditioning chemotherapy consisting of fludarabine 30 mg/m\\^2/day and cyclophosphamide 500 mg/m\\^2/day IV infusion for 3 days followed by a single infusion of brexucabtagene autoleucel at a targeted dose of 0.5 x 10\\^6 anti-CD19 CAR T cells/kg, with a maximum dose of 0.5 x 10\\^8 anti-CD19 CAR T cells for participants ≥ 100 kg on Day 0.","id":"FG002","title":"Cohort 2: 0.5 x 10^6 Brexucabtagene Autoleucel"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"41"},{"groupId":"FG002","numSubjects":"6"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"6"},{"groupId":"FG002","numSubjects":"3"}],"type":"Enrolled but never treated"},{"reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}],"type":"Enrolled, did not initiate AC"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"2"}],"type":"Full consent withdrawal"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"1"}],"type":"Lost to Follow-up"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"14"},{"groupId":"FG001","numSubjects":"74"},{"groupId":"FG002","numSubjects":"17"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"10"},{"groupId":"FG001","numSubjects":"68"},{"groupId":"FG002","numSubjects":"14"}],"type":"Safety Analysis Set (Treated Participants)"},{"achievements":[{"groupId":"FG000","numSubjects":"8"},{"comment":"Rolled over to another Long Term Follow Up (LTFU) study.","groupId":"FG001","numSubjects":"23"},{"comment":"Rolled over to another LTFU study.","groupId":"FG002","numSubjects":"5"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"51"},{"groupId":"FG002","numSubjects":"12"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Participants from 2 x 10\\^6 axicabtagene ciloleucel (AC) didn't contribute to primary and secondary analysis. The process used to manufacture axicabtagene ciloleucel was modified to manufacture brexucabtagene autoleucel (KTE-X19).","recruitmentDetails":"Participants were enrolled at study sites in United States, France, Netherlands and Germany."}